DBD Stock Analysis: Buy, Sell, or Hold?
DBD - Diebold Nixdorf, Incorporated
$73.59
2.33 (3.27%)
▲
5d:
-17.62%
30d:
-11.69%
90d:
-4.19%
WAIT
LOW Confidence
Analysis Updated: Jul 31, 2026 12:00 AM ET
Earnings: Jul 29, 2026
0d
Get Alerted When DBD Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
⏸️ WAIT FOR STABILIZATION: DBD is down 17.6% over the last 5 days. While fundamentals may be solid, catching a falling knife is risky. Wait for price to stabilize before entering.
⏸️ WAIT FOR STABILIZATION: DBD is down 17.6% over the last 5 days. While fundamentals may be solid, catching a falling knife is risky. Wait for price to stabilize before entering.
Long-Term Wealth Forecast (2031)
Based on Analyst Consensus Growth & Historical Valuation
0% (Stagnation)
50% (Hyper Growth)
EST. PRICE IN 2031
$169.51
Based on 14.5% avg growth
INTRINSIC VALUE TODAY
$105.25
30.1% Margin of Safety
How this is calculated: We use a Growth Decay Model: starting with analyst consensus growth (adjusted above) and gradually slowing it down to a long-term terminal rate (4%) by Year 5. This provides a more realistic valuation than assuming constant hyper-growth. We then apply a 12.4x Exit PE.
In-depth Analysis How we analyze
Valuation Analysis: DBD is currently trading at $73.59, which is considered oversold relative to its 30-day fair value range of $79.84 to $88.62. From a valuation perspective, the stock is trading at a discount (Forward PE: 10.5) compared to its historical average (12.4). Remarkably, the market is currently pricing in an annual earnings decline of 5.4% over the next few years. This pessimistic expectation contrasts with the company's recent 34.2% earnings growth, suggesting potential undervaluation if the company simply maintains stability.
Technical Outlook: Technically, DBD is in a uptrend. Immediate support is located at $70.47, while resistance sits at $92.08. The stock is showing strong short-term momentum, up 3.3% recently.
Market Sentiment: The stock shows a mixed technical setup (40/100), with neutral trendline and momentum signals. In the options market, Implied Volatility is low (16th percentile), suggesting options premiums are relatively cheap. This makes it an attractive time for long options strategies if you have a directional bias. Wall Street analysts see significant upside, with an average price target of $98.33 (+33.6%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, DBD is in a uptrend. Immediate support is located at $70.47, while resistance sits at $92.08. The stock is showing strong short-term momentum, up 3.3% recently.
Market Sentiment: The stock shows a mixed technical setup (40/100), with neutral trendline and momentum signals. In the options market, Implied Volatility is low (16th percentile), suggesting options premiums are relatively cheap. This makes it an attractive time for long options strategies if you have a directional bias. Wall Street analysts see significant upside, with an average price target of $98.33 (+33.6%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
OVERSOLD
Historical Trading Range
$79.84 -
$88.62
Company Quality Score
50/100
(HOLD)
Options IV Signal
16th percentile
(COMPLACENCY WARNING)
Volume Confirmation
HIGH
Confidence Score
87.3%
Protect Your Profits
Holding DBD? Use our AI-powered strategies to protect your downside while keeping your long-term position.
View Profit Protection PlanAll Signals
- BULLISH: Price oversold vs 30-day range
- BULLISH: Options cheap (IV 16th percentile)
- NEUTRAL: Mixed technical signals (40/100)
- BULLISH: High volume confirmation
- BULLISH: Strong upward momentum (+3.3%)
- BULLISH: Trading 33.6% below Wall St target ($98.33)
- WARNING: Recommendation downgraded due to -17.6% 5-day decline - wait for stabilization
Trading Range Analysis
30-Day Trading Range
$79.84 -
$88.62
Current vs Trading Range
OVERSOLD
Expected Move (7 Days)
±$4.53
(6.2%)
Support & Resistance Levels
Support Level
$70.47
Resistance Level
$92.09
Current Trend
Uptrend
Technical data as of
Jul 31, 2026
Fundamental Context
Forward P/E (Next Year Est.)
10.48
Wall Street Target
$98.33
(+33.6%)
Revenue Growth (YoY)
1.7%
Earnings Growth (YoY)
34.2%
Profit Margin
2.9%
Valuation Discount vs History
-5.4% cheaper
PE vs Historical
10.5 vs 12.4
CHEAP
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
-5.4%
(market-implied from PE analysis)
1-Year Target
$69.62
(-5%)
2-Year Target
$65.86
(-11%)
3-Year Target
$62.30
(-15%)
3-Yr Target (if PE normalizes)
(PE: 10→12)
$73.69
(+0%)
3-Year Scenarios
Using analyst projected EPS growth
Bull:
(PE: 20.7, Growth: 28.5%)
$308.73
(+320%)
Base:
(SPY PE: 10.5, Growth: 28.5%)
$156.12
(+112%)
Bear:
(PE: 8.9, Growth: 28.5%)
$132.70
(+80%)
📈
Valuation based on Current Earnings
RECOVERY PLAY: Stock looks expensive now (25x PE), but valuation improves significantly next year (10x PE) as earnings recover.
Trailing PE: 24.92 | Current EPS (TTM): $2.86
Bull Case
$156.77
(+113%)
Analyst growth 100.0%, PE expands to 27.4
Base Case
$142.52
(+94%)
Market implied 100.0%, PE stable at 24.9
Bear Case
$48.46
(-34%)
Severe decline -20.0%, PE contracts to 21.2
These are projections based on PE multiples and EPS growth scenarios, not predictions. Actual results may vary significantly.
💡
Upside Surprise Potential
If earnings stabilize (0% growth), PE could expand from 10.5 to 12.4
Stabilization Target:
$87.05
(+18.3%)
PE Expansion Potential:
+18.3%
Share & Embed Analysis
Last updated: August 02, 2026 8:09 PM ET
Data refreshes hourly during market hours. Next update: 9:09 PM
Data refreshes hourly during market hours. Next update: 9:09 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is DBD showing a specific setup today?
Insider Activity (6 Months)
0
Buys
3
Sells
Net
INSIDERS SELLING
Recent Transactions
Millstreet Capital Manag…
SELL
60833 shares
2026-04-16
Millstreet Capital Manag…
SELL
51472 shares
2026-04-15
Millstreet Capital Manag…
SELL
399929 shares
2026-04-08
Top Rated Software - Application Stocks
Top-rated stocks in Software - Application by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
INTU
Intuit Inc |
STRONG BUY
34 analysts |
$456 | 48 HOLD |
|
UBER
Uber Technologies Inc |
STRONG BUY
54 analysts |
$104 | 52 HOLD |
|
MNDY
Monday.Com Ltd |
STRONG BUY
27 analysts |
$109 | 54 HOLD |
|
CRM
Salesforce.com Inc |
STRONG BUY
55 analysts |
$242 | 45 HOLD |
|
U
Unity Software Inc |
BUY
29 analysts |
$36 | 57 HOLD |
Advanced DBD Option Strategies
Professional options setups generated by AI based on today's DBD price and gamma walls.
